Date & Time
April 6, 4:00 PM ET / 1:00 PM PT
Webinar Details provided upon RSVP Approval
About the Event
Lumeda is on a mission to commercialize a disruptive innovation in Pnotodynamic Therapy (PDT) that has the potential to improve treatment outcomes for patients with late-stage cancers. PDT improves the effectiveness of Immune Checkpoint Inhibitors by activating T Cells.
Join our webinar with Lumeda CEO, Sandy Zinke, to hear how their technology will have a major impact on millions of lives and extend the reach of ICIs from companies like Merck, Bristol-Meyers-Squibb, AstraZeneca, Roche, Regeneron and others.